Solco Healthcare US Valsartan
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
18,003 recalls, newest first
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Presence of Particulate Matter: organic and inorganic compounds detected in vials of product.
Superpotent Drug: lots out of specification for elevated sodium chloride and fluconazole assay.
Failed Stability Specifications: lot out of specification for elevated water vapor.
Superpotent Drug and Failed Stability Specifications: lot out of specification for elevated sodium chloride and elevated water vapor.
Labeling: Incorrect or Missing Lot and/or Exp Date: Product distributed without a lot number or expiration date on the outer carton.
Subpotent Drug
Temperature Abuse: Product samples of Admelog may not have been shipped at proper temperature.
Incorrect Product Formulation: wrong sunscreen product in the package.
Failed Impurities and Degradation Specifications and Subpotent Drug: out-of-specification (OOS) test results for below assay and above specification for degradants.
Presence of foreign substance: One lot fo Metformin Hydrochloride Extended Release Tablets, USP, 500 mg (500 Count) contains foreign matter identified as a piece of rubber glove detected in one tablet.
CGMP Deviations: Syringes were filled with 19mL of potassium chloride when the labels displayed a fill of 20mL.
CGMP Deviations: The manufacturer of this product recalled because they were not manufactured under current good manufacturing practices.
Presence of Particulate Matter: identified as glass and silicone material
Subpotent Drug: Stability data does not support the current expiration dating of 55 days after compounding.
Labeling: Label Error on Declared Strength: syringes of Neostigmine Methylsulfate 1 mg per mL, 5 mg per 5 mL may be incorrectly labeled as Neostigmine Methylsulfate 1 mg per mL, 3 mg per 3 mL.
Labeling: Label Error on Declared Strength: syringes of Neostigmine Methylsulfate 1 mg per mL, 5 mg per 5 mL may be incorrectly labeled as Neostigmine Methylsulfate 1 mg per mL, 3 mg per 3 mL.
Microbial Contamination of Sterile Products: Product associated with reports of adverse events indicative of infusion reactions related to microbiological contamination.
Subpotent Drug and Failed Content Uniformity.
Out-of-specification results for the Enalapril Diketopiperazine degradation product during commercial stability.
Out-of-specification results for the Enalapril Diketopiperazine degradation product during commercial stability.
Out-of-specification results for the Enalapril Diketopiperazine degradation product during commercial stability.
Microbial Contamination of Non-Sterile Products: The firm is initiating a recall of some of its products due to the potential of high microbial loads.
Microbial Contamination of Non-Sterile Products: The firm is initiating a recall of some of its products due to the potential of high microbial loads.